HOOKIPA Pharma (HOOK) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

HOOK Stock Forecast

HOOKIPA Pharma stock forecast is as follows: an average price target of $3.00 (represents a 48.51% upside from HOOK’s last price of $2.02) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

HOOK Price Target

The average price target for HOOKIPA Pharma (HOOK) is $3.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential 48.51% upside from HOOK's last price of $2.02.

HOOK Analyst Ratings

Buy

According to 4 Wall Street analysts, HOOKIPA Pharma's rating consensus is 'Buy'. The analyst rating breakdown for HOOK stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

HOOKIPA Pharma Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 11, 2022		Leerink Partners	$3.00	$1.59	88.68%	48.51%

The latest HOOKIPA Pharma stock forecast, released on Aug 11, 2022 by Leerink Partners company, set a price target of $3.00, which represents a 88.68% increase from the stock price at the time of the forecast ($1.59), and a 48.51% increase from HOOK last price ($2.02).

HOOKIPA Pharma Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$2.02	$2.02	$2.02
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of HOOKIPA Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to HOOKIPA Pharma's last price of $2.02. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 09, 2024	JMP Securities	Outperform	Outperform	Hold
Jun 05, 2024	H.C. Wainwright	Buy	Buy	Hold
May 21, 2024	RBC Capital	Buy	Buy	Hold
May 21, 2024	RBC Capital	Outperform	Outperform	Hold
Nov 15, 2022	RBC Capital	Outperform	Outperform	Hold
Aug 11, 2022	SVB Leerink	Outperform	Outperform	Hold

HOOKIPA Pharma's last stock rating was published by JMP Securities on Aug 09, 2024. The company gave HOOK a "Outperform" rating, the same as its previous rate.

HOOKIPA Pharma Financial Forecast

HOOKIPA Pharma Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Revenue	-	-	-	-	-	-	-	-	$7.41M	-	-	$3.18M	$7.83M	$2.23M	$2.75M	$1.45M	$-10.71M	$3.87M	$5.38M	$5.30M	$5.16M	$4.04M	$6.68M	$3.70M	$3.62M	$2.04M	$4.05M	$2.23M
Avg Forecast	$2.00M	$2.00M	$2.00M	$2.00M	$6.25M	$6.25M	$7.10M	$5.22M	$4.55M	$4.25M	$4.87M	$4.39M	$7.07M	$2.91M	$3.36M	$14.53M	$3.80M	$5.72M	$5.12M	$3.97M	$4.26M	$4.61M	$3.49M	$4.24M	$2.88M	$3.06M	$2.08M	$2.00M
High Forecast	$3.36M	$3.36M	$3.36M	$3.36M	$10.50M	$10.50M	$11.93M	$5.22M	$4.93M	$4.25M	$8.19M	$7.38M	$11.88M	$2.91M	$3.36M	$14.53M	$3.80M	$5.72M	$5.12M	$3.97M	$4.26M	$4.61M	$3.49M	$4.24M	$2.88M	$3.06M	$2.08M	$2.00M
Low Forecast	$640.00K	$640.00K	$640.00K	$640.00K	$2.00M	$2.00M	$2.27M	$5.22M	$4.17M	$4.25M	$1.56M	$1.40M	$2.26M	$2.91M	$3.36M	$14.53M	$3.80M	$5.72M	$5.12M	$3.97M	$4.26M	$4.61M	$3.49M	$4.24M	$2.88M	$3.06M	$2.08M	$2.00M
# Analysts	1	1	1	1	2	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	1.63%	-	-	0.72%	1.11%	0.77%	0.82%	0.10%	-2.82%	0.68%	1.05%	1.34%	1.21%	0.88%	1.92%	0.87%	1.25%	0.67%	1.95%	1.12%

HOOKIPA Pharma's average Quarter revenue forecast for Mar 24 based on 1 analysts is $5.22M, with a low forecast of $5.22M, and a high forecast of $5.22M. HOOK's average Quarter revenue forecast represents a -29.58% decrease compared to the company's last Quarter revenue of $7.41M (Dec 23).

HOOKIPA Pharma EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	$-16.85M	$-22.67M	$-21.47M	$-22.66M	$-13.59M	$-17.41M	$-15.26M	$-16.65M	$-22.80M	$-18.71M	$-15.72M	$-15.92M	$-9.65M	$-12.76M	$-6.45M	$-10.29M	$-10.85M	$-10.38M	$-10.93M	$-8.55M
Avg Forecast	$-2.00M	$-2.00M	$-2.00M	$-2.00M	$-6.25M	$-6.25M	$-7.10M	$-5.22M	$-4.55M	$-4.25M	$-4.87M	$-4.39M	$-7.07M	$-2.91M	$-3.36M	$-13.12M	$-3.80M	$-5.72M	$-5.12M	$-15.92M	$-4.26M	$-4.61M	$-3.49M	$-10.04M	$-2.88M	$-3.06M	$-2.08M	$-32.48M
High Forecast	$-640.00K	$-640.00K	$-640.00K	$-640.00K	$-2.00M	$-2.00M	$-2.27M	$-5.22M	$-4.17M	$-4.25M	$-1.56M	$-1.40M	$-2.26M	$-2.91M	$-3.36M	$-10.49M	$-3.80M	$-5.72M	$-5.12M	$-12.73M	$-4.26M	$-4.61M	$-3.49M	$-8.04M	$-2.88M	$-3.06M	$-2.08M	$-25.99M
Low Forecast	$-3.36M	$-3.36M	$-3.36M	$-3.36M	$-10.50M	$-10.50M	$-11.93M	$-5.22M	$-4.93M	$-4.25M	$-8.19M	$-7.38M	$-11.88M	$-2.91M	$-3.36M	$-15.74M	$-3.80M	$-5.72M	$-5.12M	$-19.10M	$-4.26M	$-4.61M	$-3.49M	$-12.05M	$-2.88M	$-3.06M	$-2.08M	$-38.98M
Surprise %	-	-	-	-	-	-	-	-	3.70%	5.33%	4.41%	5.16%	1.92%	5.99%	4.55%	1.27%	5.99%	3.27%	3.07%	1.00%	2.26%	2.76%	1.85%	1.02%	3.76%	3.39%	5.26%	0.26%

undefined analysts predict HOOK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than HOOKIPA Pharma's previous annual EBITDA (undefined) of $NaN.

HOOKIPA Pharma Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	$-24.82M	$-19.07M	$-18.02M	$-19.89M	$-12.54M	$-15.57M	$-16.36M	$-15.79M	$-21.23M	$-20.04M	$-17.15M	$-17.24M	$-12.47M	$-13.59M	$-7.09M	$-10.93M	$-10.24M	$-11.38M	$-12.08M	$-9.33M
Avg Forecast	$-25.08M	$-25.08M	$-23.82M	$-22.57M	$-11.66M	$-16.05M	$-15.70M	$-12.85M	$-35.41M	$-26.33M	$-26.12M	$-28.34M	$-25.97M	$-34.03M	$-45.14M	$-14.16M	$-71.29M	$-68.55M	$-65.20M	$-17.24M	$-70.43M	$-52.45M	$-57.68M	$-10.67M	$-58.31M	$-79.31M	$-63.95M	$-35.44M
High Forecast	$-2.91M	$-2.91M	$-2.76M	$-2.62M	$-1.35M	$-1.86M	$-1.82M	$-1.49M	$-25.34M	$-3.05M	$-3.03M	$-3.29M	$-3.01M	$-34.03M	$-45.14M	$-11.33M	$-71.29M	$-68.55M	$-65.20M	$-13.79M	$-70.43M	$-52.45M	$-57.68M	$-8.53M	$-58.31M	$-79.31M	$-63.95M	$-28.36M
Low Forecast	$-47.25M	$-47.25M	$-44.88M	$-42.52M	$-21.97M	$-30.24M	$-29.59M	$-24.21M	$-45.47M	$-49.61M	$-49.21M	$-53.39M	$-48.93M	$-34.03M	$-45.14M	$-16.99M	$-71.29M	$-68.55M	$-65.20M	$-20.69M	$-70.43M	$-52.45M	$-57.68M	$-12.80M	$-58.31M	$-79.31M	$-63.95M	$-42.53M
Surprise %	-	-	-	-	-	-	-	-	0.70%	0.72%	0.69%	0.70%	0.48%	0.46%	0.36%	1.12%	0.30%	0.29%	0.26%	1.00%	0.18%	0.26%	0.12%	1.02%	0.18%	0.14%	0.19%	0.26%

HOOKIPA Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. HOOK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

HOOKIPA Pharma SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	$3.10M	$4.91M	$4.45M	$4.90M	$3.82M	$4.94M	$5.03M	$4.97M	$-31.02M	$4.34M	$5.09M	$4.31M	$3.22M	$2.44M	$2.75M	$3.16M	$2.92M	$3.33M	$2.21M	$1.52M
Avg Forecast	$2.20M	$2.20M	$2.20M	$2.20M	$6.88M	$6.88M	$7.81M	$5.74M	$5.01M	$4.68M	$5.36M	$4.83M	$7.78M	$3.10M	$3.57M	$3.92M	$4.05M	$6.09M	$5.46M	$4.23M	$4.54M	$4.91M	$3.72M	$3.08M	$3.07M	$3.26M	$2.21M	$2.13M
High Forecast	$3.70M	$3.70M	$3.70M	$3.70M	$11.55M	$11.55M	$13.12M	$5.74M	$5.42M	$4.68M	$9.01M	$8.11M	$13.07M	$3.10M	$3.57M	$4.70M	$4.05M	$6.09M	$5.46M	$4.23M	$4.54M	$4.91M	$3.72M	$3.70M	$3.07M	$3.26M	$2.21M	$2.13M
Low Forecast	$704.16K	$704.16K	$704.16K	$704.16K	$2.20M	$2.20M	$2.50M	$5.74M	$4.59M	$4.68M	$1.72M	$1.55M	$2.49M	$3.10M	$3.57M	$3.13M	$4.05M	$6.09M	$5.46M	$4.23M	$4.54M	$4.91M	$3.72M	$2.47M	$3.07M	$3.26M	$2.21M	$2.13M
Surprise %	-	-	-	-	-	-	-	-	0.62%	1.05%	0.83%	1.01%	0.49%	1.59%	1.41%	1.27%	-7.66%	0.71%	0.93%	1.02%	0.71%	0.50%	0.74%	1.02%	0.95%	1.02%	1.00%	0.71%

HOOKIPA Pharma's average Quarter SG&A projection for Mar 24 is $5.74M, based on 1 Wall Street analysts, with a range of $5.74M to $5.74M. The forecast indicates a 85.36% rise compared to HOOK last annual SG&A of $3.10M (Dec 23).

HOOKIPA Pharma EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	$-0.25	$-0.17	$-0.22	$-0.28	$-0.23	$-0.22	$-0.23	$-0.35	$-0.65	$-0.61	$-0.52	$-0.53	$-0.46	$-0.53	$-0.28	$-0.43	$-0.40	$-0.45	$-0.63	$-0.37
Avg Forecast	$-2.00	$-2.00	$-1.90	$-1.80	$-0.93	$-1.28	$-1.25	$-1.02	$-2.82	$-2.10	$-2.08	$-2.26	$-2.07	$-2.71	$-3.60	$-2.40	$-5.69	$-5.47	$-5.20	$-5.33	$-5.62	$-4.18	$-4.60	$-4.20	$-4.65	$-6.33	$-5.10	$-14.80
High Forecast	$-0.23	$-0.23	$-0.22	$-0.21	$-0.11	$-0.15	$-0.15	$-0.12	$-2.02	$-0.24	$-0.24	$-0.26	$-0.24	$-2.71	$-3.60	$-2.40	$-5.69	$-5.47	$-5.20	$-5.33	$-5.62	$-4.18	$-4.60	$-4.20	$-4.65	$-6.33	$-5.10	$-14.80
Low Forecast	$-3.77	$-3.77	$-3.58	$-3.39	$-1.75	$-2.41	$-2.36	$-1.93	$-3.63	$-3.96	$-3.92	$-4.26	$-3.90	$-2.71	$-3.60	$-2.40	$-5.69	$-5.47	$-5.20	$-5.33	$-5.62	$-4.18	$-4.60	$-4.20	$-4.65	$-6.33	$-5.10	$-14.80
Surprise %	-	-	-	-	-	-	-	-	0.09%	0.08%	0.11%	0.12%	0.11%	0.08%	0.06%	0.15%	0.11%	0.11%	0.10%	0.10%	0.08%	0.13%	0.06%	0.10%	0.09%	0.07%	0.12%	0.02%

According to undefined Wall Street analysts, HOOKIPA Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HOOK previous annual EPS of $NaN (undefined).

HOOKIPA Pharma Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
PDSB	PDS Bio	$1.96	$9.00	359.18%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
MREO	Mereo BioPharma Group	$3.40	$8.00	135.29%	Buy
AMLX	Amylyx Pharmaceuticals	$4.28	$8.25	92.76%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
HOOK	HOOKIPA Pharma	$2.13	$3.00	40.85%	Buy

HOOK Forecast FAQ

Is HOOKIPA Pharma a good buy?

Yes, according to 4 Wall Street analysts, HOOKIPA Pharma (HOOK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of HOOK's total ratings.

What is HOOK's price target?

HOOKIPA Pharma (HOOK) average price target is $3 with a range of $3 to $3, implying a 48.51% from its last price of $2.02. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will HOOKIPA Pharma stock go up soon?

According to Wall Street analysts' prediction for HOOK stock, the company can go up by 48.51% (from the last price of $2.02 to the average price target of $3), up by 48.51% based on the highest stock price target, and up by 48.51% based on the lowest stock price target.

Can HOOKIPA Pharma stock reach $3?

HOOK's average twelve months analyst stock price target of $3 does not support the claim that HOOKIPA Pharma can reach $3 in the near future.

What are HOOKIPA Pharma's analysts' financial forecasts?

HOOKIPA Pharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $24.82M (high $38.14M, low $11.49M), average EBITDA is $-24.816M (high $-11.488M, low $-38.144M), average net income is $-56.268M (high $-6.527M, low $-106M), average SG&A $27.3M (high $41.97M, low $12.64M), and average EPS is $-4.487 (high $-0.521, low $-8.454). HOOK's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $8M (high $13.44M, low $2.56M), average EBITDA is $-8M (high $-2.56M, low $-13.44M), average net income is $-96.549M (high $-11.2M, low $-182M), average SG&A $8.8M (high $14.79M, low $2.82M), and average EPS is $-7.7 (high $-0.893, low $-14.507).

Did the HOOK's actual financial results beat the analysts' financial forecasts?

Based on HOOKIPA Pharma's last annual report (Dec 2022), the company's revenue was $14.25M, which missed the average analysts forecast of $27.86M by -48.86%. Apple's EBITDA was $-73.155M, beating the average prediction of $-26.449M by 176.59%. The company's net income was $-65.145M, missing the average estimation of $-119M by -45.40%. Apple's SG&A was $18.76M, beating the average forecast of $18.37M by 2.14%. Lastly, the company's EPS was $-2.5, missing the average prediction of $-10.786 by -76.82%. In terms of the last quarterly report (Dec 2023), HOOKIPA Pharma's revenue was $7.41M, beating the average analysts' forecast of $4.55M by 62.79%. The company's EBITDA was $-16.851M, beating the average prediction of $-4.55M by 270.35%. HOOKIPA Pharma's net income was $-24.818M, missing the average estimation of $-35.409M by -29.91%. The company's SG&A was $3.1M, missing the average forecast of $5.01M by -38.16%. Lastly, the company's EPS was $-0.25, missing the average prediction of $-2.824 by -91.15%